Insider trade

Director sold ~$265K of MRNA shares in the open market

Traded May 1, 2026 · Filed May 4, 2026

ModernaMRNA

~$265K
Reported value · 5,682 sh @ $46.63: 12K
Holds after · shares reported: +316.4%
stock since the trade · S&P 500 +6.0%, $45.37 → $188.94 on Oct 1

Why it stands out

A board member of Moderna sold $265K of Moderna shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 1, 2026
Reporting period: Not applicable
Filed with the SEC: May 4, 2026

Director$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$264,952

Shares × reported transaction price

Timing vs results

on the day of results (May 1, 2026), 91 days before results of Jul 31, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $45.37 on May 1, 2026, 103% above its 52-week low and 22% below its high, after a 13% drop over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $57.80 (Mar 4, 2026), 65% of the way up, from 251 adjusted closes. 30 trading days earlier: $52.37 on Mar 19, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+14.0%	+2.0%	+12.1%
30 days	+10.4%	+4.6%	+5.8%
90 days	+18.1%	+4.7%	+13.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001682852-26-000070
Filed / recorded: May 4, 2026, 9:25 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Moderna, Inc.
Issuer CIK: 1682852
Ticker: MRNA
Reporting person: Abbas Hussain
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 1, 2026
Transaction code: S
Shares / units: 5,682
Price per share: $46.63
Acquired / disposed: Disposed (D)
Shares owned after: 12,066
Ownership form: Direct
Amendment: No

Footnotes from the filing

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.